Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024)
Travere Therapeutics (TVTX) reported Cash from Discontinued Operations of 7089000.0 for Q4 2024, down 16.21% on a YoY basis from 8460751.32 in Q1 2024, and down 14278.0% quarter-over-quarter from 50000.0 in Q3 2024.
Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024) Analysis & Trends
Travere Therapeutics has reported Cash from Discontinued Operations for 3 years, with the latest figure at 7089000.0 in Q4 2024.
- For the quarter ending Q4 2024, Cash from Discontinued Operations fell 16.21% year-over-year to 7089000.0; the trailing twelve-month figure through Sep 2025 stood at 7089000.0 (down 9.7% YoY), and the FY2024 full-year result was 7451000.0, down 116.44% from the prior year.
- Cash from Discontinued Operations for Q4 2024 stood at 7089000.0, down from 50000.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 22064000.0 in Q4 2022, with the low at 7089000.0 in Q4 2024.
- Historically, Cash from Discontinued Operations has averaged 6661000.0 across 3 years, with a median of 50000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Discontinued Operations slumped 127.65% — and 2024, when it retreated 16.21%.
- Travere Therapeutics' Cash from Discontinued Operations stood at 22064000.0 in 2022, then tumbled by 127.65% to 6100000.0 in 2023, then declined by 16.21% to 7089000.0 in 2024.
- The last three Cash from Discontinued Operations figures came in at 7089000.0 (Q4 2024), 50000.0 (Q3 2024), and 309000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -59.14 Mn |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -7.09 Mn |
| Dec 31, 2024 | -7.09 Mn |
| Sep 30, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | -309,000.00 |
| Jun 30, 2024 | -309,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -6.10 Mn |
| Dec 31, 2023 | -6.10 Mn |
| Sep 30, 2023 | 15.29 Mn |
| Sep 30, 2023 | 15.29 Mn |
| Jun 30, 2023 | 18.61 Mn |
| Jun 30, 2023 | 18.61 Mn |
| Mar 31, 2023 | 17.53 Mn |
| Mar 31, 2023 | 17.53 Mn |
| Dec 31, 2022 | 22.06 Mn |
| Dec 31, 2022 | 22.06 Mn |